Table of Content


Introduction
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..2), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1)
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Products under Development by Companies, H1 2019 (Contd..3), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AptaTargets SL, H1 2019
Pipeline by Batu Biologics Inc, H1 2019
Pipeline by Cyxone AB, H1 2019
Pipeline by Eisai Co Ltd, H1 2019
Pipeline by eTheRNA Immunotherapies NV, H1 2019
Pipeline by EyeGene Inc, H1 2019
Pipeline by GigaGen Inc, H1 2019
Pipeline by GlaxoSmithKline Plc, H1 2019
Pipeline by Harbor Therapeutics Inc, H1 2019
Pipeline by Immune Design Corp, H1 2019
Pipeline by Immunovo BV, H1 2019
Pipeline by NovImmune SA, H1 2019
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
Pipeline by Vascular Biogenics Ltd, H1 2019
Dormant Products, H1 2019
Discontinued Products, H1 2019